Novartis And Fudan University To Set Up Cancer Research Lab
This article was originally published in PharmAsia News
Novartis and Fudan University will jointly conduct research focusing on developing new approaches to understand the causes of cancer. The announcement was made at the groundbreaking ceremony of China Novartis Institutes For Biomedical Research in Shanghai that will accommodate more than 400 researchers in its phase I construction. Researchers from both Novartis Shanghai R&D Center and Fudan will work at a joint lab in the university campus, adopting innovative molecular genetics techniques to develop disease models for new target discovery for cancer therapy. The initial efforts will concentrate on research on liver cancer. (Click here for more - Chinese Language)
You may also be interested in...
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)
Novartis' Head of Corporate Research Paul Herrling and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, sat down recently with PharmAsia News on the sidelines of the China 2008 Pharmaceutical R&D Summit in Shanghai to discuss Novartis' R&D plans in China and the Pacific Rim.
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.